Evidence map›Paper›PMID 42034784›Full record

ArticleScientific reports2026

Antibiotic treatment reveals the contributions of the gut microbiome to CLN2 disease in the central and enteric nervous system.

Ewa A Ziółkowska, Paris Nix, Bartłomiej Olszowy, Letitia L Williams, Elizabeth M Eultgen, Agnieszka Nowacka, Marta Celorrio, Stuart H Friess, Robert O Heuckeroth, Jonathan D Cooper

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ewa A ZiółkowskaDepartment of Pediatrics, School of Medicine, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, MO, 63110, USA.
Paris NixDepartment of Pediatrics, School of Medicine, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, MO, 63110, USA.
Bartłomiej OlszowyDepartment of Medicine, Endocrinology, Edison Family Center for Genome Sciences and Systems Biology, Washington University in St. Louis, School of Medicine, St. Louis, MO, 63110, USA.
Letitia L WilliamsDepartment of Pediatrics, School of Medicine, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, MO, 63110, USA.
Elizabeth M EultgenDepartment of Pediatrics, School of Medicine, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, MO, 63110, USA.
Agnieszka NowackaDepartment of Neurosurgery, Nicolas Copernicus University in Toruń, Collegium Modicum in Bydgoszcz, ul. Curie Skłodowskiej 9, 85-094, Bydgoszcz, Poland.
Marta CelorrioDepartment of Pediatrics, School of Medicine, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, MO, 63110, USA.
Stuart H FriessDepartment of Pediatrics, School of Medicine, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, MO, 63110, USA.
Robert O HeuckerothChildren's Hospital of Philadelphia Research Institute, Children's Hospital of Philadelphia (CHOP), Philadelphia, PA, 19104, USA.
Jonathan D CooperDepartment of Pediatrics, School of Medicine, Washington University in St. Louis, 660 S Euclid Ave, St. Louis, MO, 63110, USA. cooperjd@wustl.edu.

Funding

Defining non-genetic mechanisms that prevent death in a Hirschsprung disease mouse modelR01DK129691 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI HEUCKEROTH, ROBERT O · 2021 to 2024
$2.3M
Characterizing and testing the efficacy of AAV-mediated gene therapy in a sheep model of CLN1 disease.R01NS124655 · NINDS · WASHINGTON UNIVERSITY · PI COOPER, JONATHAN D · 2022 to 2025
$1.9M
Mechanistic human studies to prevent Hirschsprung-associated enterocolitisR01DK141691 · NIDDK · CHILDREN'S HOSP OF PHILADELPHIA · PI ROBERT O HEUCKEROTH · 2025 to 2026
$1.4M
Cellular Mechanisms of Enteric Nervous System Damage in CLN2 DiseaseR01NS140682 · NINDS · WASHINGTON UNIVERSITY · PI JONATHAN D COOPER · 2025 to 2026
$1.3M
Defining and treating enteric nervous system damage in Cln1 diseaseR21NS116574 · NINDS · WASHINGTON UNIVERSITY · PI COOPER, JONATHAN D · 2020 to 2020
$454k
Defining and treating peripheral nervous system dysfunction in Cln1 diseaseR21NS126907 · NINDS · WASHINGTON UNIVERSITY · PI COOPER, JONATHAN D · 2022 to 2023
$433k
NIDDK NIH HHS R01 DK129691NIDDK NIH HHS R01 DK141691NIH HHS R01 DK129691NINDS NIH HHS R01 NS124655NINDS NIH HHS R01 NS140682NINDS NIH HHS R21 NS116574NINDS NIH HHS R21 NS126907
6 · The paper itself

Abstract

The Neuronal Ceroid Lipofuscinoses (NCLs) are fatal inherited lysosomal storage diseases, with pronounced neuron loss in the central nervous system (CNS). Gastrointestinal issues are frequently reported by people with NCLs, although mechanisms underlying these symptoms are poorly understood. We recently demonstrated degeneration occurs within the enteric nervous system (ENS) in several NCLs. Given that the gut microbiome has been shown to be altered a CLN2 mouse model (Tpp1

Indexed as

Anti-Bacterial AgentsCentral Nervous SystemEnteric Nervous SystemGastrointestinal MicrobiomeNeuronal Ceroid-LipofuscinosesAnimalsBrainDipeptidyl-Peptidases and Tripeptidyl-PeptidasesDisease Models, AnimalMiceNeuronsTripeptidyl-Peptidase 1Anti-Bacterial AgentsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesTpp1 protein, mouseTripeptidyl-Peptidase 1Antibiotic treatmentBrain–gut axisEnteric nervous systemGut microbiotaNeuroinflammationNeuronal ceroid lipofuscinosis

Identifiers

PMID42034784
PMCPMC13279791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.